3Rizkalla HF, Higgins M, Kelehan P, et al. Pathological findings associated with the presence of a Mirena intrauterine system at hysterectomy[ J]. Int J Gynecol Pathol, 2008, 27 (1) :74 -78.
4KoH S, Singh K. The effect of lenvonorgestrel - releasing intrauterine system use on menstrual blood loss and the hemostatic, fibfinolytic/inhibitor systems in women with menorrhagia [ J ]. J Thromb Haemost, 2007, 5( 1 ) :133 - 138.
5Paivi Pakarinen, Tapani Luukkainen. Treatment of menorrhagia with an LNG- IUS[ J ]. Contraception, 2007, 75:S118 -S122.
6Sevtap K, Beril Y, Melike D, et al. The effect of lenvonorgestrel - releasing intrauterine device n on menorrhagia in women taking anticoagulant medication after cardiac valve replacement [ J ]. Contraception, 2009,80 : 152 - 157.
7Petta CA, Ferriani RA, Abrao MS, et al. Randomized clinical trial of a lenvonorgestrel -releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis[ J]. Hum Reprod, 2005, 20(7) :1993 -1998.
10Cho SH, Nam A, Kim HY, et al. Clinical effects of the lenvonoigestrelreleasing intrauterine device in patients with adenomyosis[ J]. Am J Obstet Gynecol, 2008, 198(4) : 373e371 -373e377.
6Higham JM, O'Brien PMS, Shaw RW. Assessment of menstrual, bloodloss using a picforal. Chart. Br J Obstetr Gynecol, 1990, 97 (70) : 74
7Sivin I, Stem J. Health during prolonged use of levonorgestrel. 20 mierograms/d and the copper Tcu 380Ag intrauterine contraceptive devices : a multicenter study. International Committee for Contraception Research (ICCR). Fortil Steril, 1994, 61(1): 70
8Rutanen EM.Endometrial response to intrauterine release of leboorgestrel.Gynecol Forum,1998,3:11-14.
9French R,Coean F,Mansour D,et al.Hormmonally impregnated intrauterine systems (IUSs) versus other form of reversible conreaceptives as effective methods of preventing pregnancy Cochirane.Database Syst Bey,2001,2:CD001776.
10Wildemeersch D,Janssens D,Schacht E,et al.Intrauterine levonorgestrel delivered by a frameless system,combined with systenmic estrogen:acceptability and endometrial safety after 3 years of use in peri -and postmenopausal women.Gynecol Endocrinol,2005,20:336-342.
2Kaunitz AM, Inki P. The levonorgestrel - releasing intrau- terine system in heavy menstrual bleeding., a benefit - risk re- view. Drugs, 2012, 72 193-215.
3Wildemeersch D, Andrade A. Review of c]iniea] experience with the frameless LNG - IUS for contraception and treat- ment of heavy menstrual bleeding. Gynecol Endocrinol, 2010, 26.. 383-389.
4Higham JM, O'Brien PM, Shaw RW. Assessment of men- strual blood loss using a pictorial chart. Obstet Gynecol, 1990, 97: 734-739.
5Vereide AB, Kaino T, Sager G, et al. Effect of ]evonorg- estrel IUD and oral medroxy progesterone eacetate on glandu- lar and stroma] progesterone receptors (PRA and PRB), and estrogen receptors (ER-aIPhaandER-beta) inhuman endometrial hyperplasia. Gyneco] Oncol, 2006, 101: 214- 223.
6Bukulmez O, Hardy DB, Cart BR, et al. Inflammatory sta- tus influences aromatase and steroid receptor expression in endometriosis. Endocrinology, 2008, 149: 1190- 1204.
7Scarselli G, Bargelli G, Taddei GL, et al. Levonorgestrel- releasing intrauterine system (LNG- IUS) as an effective treatment option for endometrial hyperplasia: a 15 - year fol- low- up study. FertilSteril, 2011, 95: 420-422.
8Souza SS, Camargos AF, Rezende CP, et al. A randomized prospective trial comparing the levonorgestrel - releasing in- trauterine system with thermal balloon ablation for the treat- ment of heavy menstrual bleeding. Contraception, 2010, 81: 226- 231.
9Khalil M, Aldohami H, Farid GR, et al. Comparative study between levonorgestrel - releasing intrauterine system and thermal balloon endometrial ablation in the treatment of idio- pathicmenorrhagia. BJOG, 2012, 119, 202.
